SCHEMBL2295220

SCHEMBL2295220

COc1cc(CO)ccc1Br

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 2/20 0.47
TSHR P16473 2/20 0.47
ALOX15 P16050 1/20 0.47
HTT P42858 1/20 0.47
NPC1 O15118 1/20 0.45
POLB P06746 1/20 0.45
RAB9A P51151 1/20 0.45
CA2 P00918 1/20 0.45
ABL1 P00519 1/20 0.44
RIN1 Q13671 1/20 0.44
ACHE P22303 1/20 0.43
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.42
TTR P02766 1/20 0.42
MMP1 P03956 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
HTR2A P28223 1/20 0.42
MAPK1 P28482 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31620813 1.00 HSD17B10 (0.47) HSD17B10TSHRALOX15HTTNPC1
SCHEMBL2500053 0.86 MAPT (0.56) HSD17B10TSHRALOX15HTTCA2
SCHEMBL31236986 0.85 TAAR1 (0.47) TSHRPOLBCA2ALDH1A1MAPT
SCHEMBL8715027 0.85 TAAR1 (0.47) TSHRPOLBCA2ALDH1A1MAPT
SCHEMBL23673569 0.82 SLC6A4 (0.42) HSD17B10TSHRALOX15HTTNPC1
SCHEMBL17295146 0.82 TNKS2 (0.60) TSHRPOLBCYP4A11MAPK1TAAR1
SCHEMBL29887121 0.82 SLC6A4 (0.42) HSD17B10TSHRALOX15HTTNPC1
SCHEMBL13698783 0.82 PTGS2 (0.52) HTTCA2ALDH1A1MAPTHTR2A
SCHEMBL2296988 0.82 CA2 (0.47) POLBCA2ALDH1A1MAPTHTR2A
SCHEMBL29725217 0.82 CA2 (0.47) POLBCA2ALDH1A1MAPTHTR2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3526186-B1 SUBSTITUTED HYDROXYSTILBENES AND THEIR THERAPEUTIC APPLICATIONS RESOLVEX PHARMACEUTICALS INC (CA) 2022-05-04 EP claimed
CN-109890784-B Substituted hydroxystyrenes and therapeutic uses thereof 瑞泽制药公司 2022-04-29 CN claimed
EP-3526186-A1 SUBSTITUTED HYDROXYSTILBENES AND THEIR THERAPEUTIC APPLICATIONS Resolvex Pharmaceuticals Inc. (CA) 2019-08-21 EP claimed
WO-2018068131-A1 SUBSTITUTED HYDROXYSTILBENES AND THEIR THERAPEUTIC APPLICATIONS RESOLVEX PHARMACEUTICALS INC. (CA) 2018-04-19 WO claimed
US-9725406-B1 Substituted hydroxystilbenes and their therapeutic applications RESOLVEX PHARMACEUTICALS INC. (CA) 2017-08-08 US claimed
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2025-12-23 US disclosed
CN-115151553-B Boric acid derivatives 首药控股(北京)股份有限公司 2025-06-13 CN disclosed
CN-118496142-A Aryl alkylamine compound and preparation method and application thereof 仁合益康集团有限公司 2024-08-16 CN disclosed
US-12054660-B2 Compound, composition, cured substance, optically anisotropic body, optical element, and light guide element FUJIFILM CORPORATION (JP) 2024-08-06 US disclosed
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) 2024-07-04 US disclosed
EP-3656754-B1 OLEFIN POLYMERIZATION CATALYST COMPRISING CYCLOTRIVERATRYLENE AND DERIVATIVES THEREOF CHINA PETROLEUM & CHEM CORP (CN) 2024-05-29 EP disclosed
CN-115028637-B Triazolopyrimidine compounds and their use for the treatment of cancer 迪哲(江苏)医药股份有限公司 2024-03-22 CN disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed
WO-2008012470-A2 SUBSTITUTED IMIDAZOLONE DERIVATIVES, PREPARATION AND USES GENFIT (FR) 2008-01-31 WO disclosed
US-6476021-B1 Compounds having cGMP-PDE inhibitory effect MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2002-11-05 US disclosed
EP-1048666-A1 NOVEL COMPOUNDS HAVING cGMP-PDE INHIBITORY EFFECT MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2000-11-02 EP disclosed
EP-0230755-B1 1-PHENYL-3-BENZAZEPINES SMITHKLINE BEECHAM CORPORATION (US) 1990-05-16 EP disclosed
US-4707483-A 1-phenyl-3-benzazepines and their use for treating gastrointestinal motility disorders SMITHKLINE BECKMAN CORPORATION (US) 1987-11-17 US disclosed
EP-0244088-A2 1-Phenyl-3-benzazepine compounds and medicaments containing these compounds for treating gastrointestinal motility disorders SMITHKLINE BEECHAM CORPORATION (US) 1987-11-04 EP disclosed
EP-0230755-A1 1-Phenyl-3-benzazepines SMITHKLINE BEECHAM CORPORATION (US) 1987-08-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12503473-B2 Triazolopyrimidine compounds and their use in treating cancer ABCC4, ABCB1, SLC16A3 HSD17B10 3684/4885TSHR 1609/4885ALOX15 4446/4885
US-12054660-B2 Compound, composition, cured substance, optically anisotropic body, optical element, and light guide element SP1, C5, ZYX HSD17B10 4588/4885TSHR 4560/4885ALOX15 759/4885
US-20240217980-A1 TRIAZOLOPYRIMIDINE COMPOUNDS AND THEIR USE IN TREATING CANCER ABCC4, ABCB1, SLC16A3 HSD17B10 3684/4885TSHR 1609/4885ALOX15 4446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.